Viewpoint Therapeutics, Inc.

SAN FRANCISCO, CA · Founded 2014 · CIK 0001673242 · Biotech · Acquired

Pharmacological chaperone small molecules that stabilize misfolded myocilin protein to treat myocilin-linked open-angle glaucoma

Grants
$447K
2 awards
Sector median: 1
Raised
$25M
2 Form D · Mar 2018
103 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a Topical Treatment for Cataract$221,978
Private capital raisedForm D · SEC$3,981,337
Private capital raisedForm D · SEC$20,935,629
Federal grantDepartment of Health and Human Services · Phase I · Pharmacological chaperones for the treatment of Open-Angle Glaucoma$225,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1494MITOSENSE, INC.—$2.2M
1495GFREE BIO, LLC——
1496BEXION PHARMACEUTICALS, INC.——
1497Viewpoint Therapeutics, Inc.—$25M
1498Enzyme by Design Inc.——
1499Calporta Therapeutics——
1500Atavistik Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Mark Blumenkranz, M.D.Director
  • Douglas CrawfordDirector
  • Emmett Cunningham, Jr.Director
  • Jason GestwickiDirector
  • Ed HurwitzDirector · Executive Officer
  • Heath LukatchDirector
  • Leah MakleyDirector · Executive Officer
  • Peter MoldtDirector

Patents

USPTO · 0 granted of 10
  • Compounds For Treating Near Vision Disordersapplication
  • Compounds And Formulations For Treating Ophthalmic Diseasesapplication
  • Compounds For Treating Near Vision Disordersapplication
  • Compounds For Treating Near Vision Disordersapplication
  • Compounds And Formulations For Treating Ophthalmic Diseasesapplication
  • Nanoparticle Formulations Of 25-Hydroxycholesterolapplication
  • Microemulsion formulations of 25-hydroxycholesterolapplication
  • Compounds And Formulations For Treating Ophthalmic Diseasesapplication
  • Pharmacological Chaperones For Inhibition Of Amyloid Formation And Formulations Thereofapplication
  • Compounds And Formulations For Treating Ophthalmic Diseasesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.